Tezepelumab, an anti-TSLP antibody which regulates Th2 immunity through Th2 and ILC2 cells, has been shown to reduce severe asthma exacerbations, blood eosinophil levels, total serum IgE, and FeNO and to improve FEV1 [19,30,105,113,114]. The gene discussed is TSLP; the disease is asthma.